Description
CJC-1295 No DAC + Ipamorelin 10mg — Dual Growth Hormone Secretagogue Research Combination
Each vial supplied by Core Research contains 5mg of CJC-1295 No DAC and 5mg of Ipamorelin, lyophilised together as a single research-grade preparation. Both peptides are verified by reverse-phase high-performance liquid chromatography (RP-HPLC) to a minimum purity of ≥99.0%, with identity confirmed by electrospray ionisation mass spectrometry (ESI-MS).
CJC-1295 No DAC is a 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH 1-44).
Compound Identity Matrix
| Attribute | CJC-1295 No DAC (Mod-GRF 1-29) | Ipamorelin |
|---|---|---|
| INN / Common Name | Modified GRF 1-29 / CJC-1295 No DAC | Ipamorelin |
| CAS Number | 863288-34-0 | 170851-70-4 |
| Molecular Formula | C152H252N44O42 | C38H49N9O5 |
| Molecular Weight | 3,367.97 Da | 711.87 Da |
| Receptor Target | GHRHR (Growth Hormone-Releasing Hormone Receptor) | GHSR-1a (Ghrelin Receptor) |
| Mechanism Class | GHRH analogue / GHRHR agonist | Ghrelin mimetic / GHSR-1a agonist |
| Supplied Quantity | 5mg CJC-1295 No DAC + 5mg Ipamorelin per vial (10mg total) | |
Analytical Documentation and Quality Release Specification
Every batch of CJC-1295 No DAC + Ipamorelin 10mg undergoes a two-tier analytical release protocol before dispatch from Core Research. The primary purity assessment is performed by reverse-phase HPLC using a C18 stationary phase with UV detection at 220 nm; both peptide components are resolved and quantified independently within the co-lyophilised matrix. The minimum release specification for each component is ≥99.0% purity by area normalisation. Identity confirmation is provided by ESI-MS, with observed mass-to-charge ratios compared against theoretical values for CJC-1295 No DAC ([M+4H]4+ = 842.50 Da) and Ipamorelin ([M+H]+ = 712.88 Da). Endotoxin content is assessed by the Limulus Amebocyte Lysate (LAL) kinetic turbidimetric method and must be below 1.0 EU/mg for release. Residual moisture in the lyophilised cake is confirmed below 5.0% by Karl Fischer titration. Batch-specific Certificate of Analysis (CoA) documents are available through the Core Research CoA Portal and are included with each order.
| Test Parameter | Method | Specification |
|---|---|---|
| CJC-1295 No DAC Purity | RP-HPLC (C18, UV 220 nm) | ≥99.0% by area normalisation |
| Ipamorelin Purity | RP-HPLC (C18, UV 220 nm) | ≥99.0% by area normalisation |
| Endotoxin | LAL Kinetic Turbidimetric | <1.0 EU/mg |
| Residual Moisture | Karl Fischer Titration | <5.0% |
| Appearance | Visual inspection | White to off-white lyophilised powder, free of visible particulates |
Analytical Note — Core Research Quality Team
The two-component co-lyophilised format requires independent chromatographic resolution of CJC-1295 No DAC and Ipamorelin within the same preparation. Both components are resolved on a C18 column under gradient conditions and quantified by area normalisation. ESI-MS is performed on the combined preparation, with both peptide masses confirmed against theoretical values in a single acquisition. Batch-specific CoA documents report both components independently.
Ipamorelin: Selective GHSR-1a Agonism
Ipamorelin acts at the growth hormone secretagogue receptor 1a (GHSR-1a), a constitutively active class A GPCR expressed in the anterior pituitary, hypothalamus, and peripheral tissues. The resulting calcium transient in somatotroph cells is the proximate trigger for GH vesicle exocytosis. Ipamorelin’s selectivity profile is a defining research characteristic: unlike GHRP-2 and GHRP-6, which produce significant co-secretion of ACTH and cortisol at effective concentrations, Ipamorelin demonstrates minimal activity at the ACTH, cortisol, and prolactin axes in in vitro assays.
Format Specification and Storage
| Parameter | Specification |
|---|---|
| Format | Lyophilised powder in sealed glass vial |
| Fill Quantity | 5mg CJC-1295 No DAC + 5mg Ipamorelin (10mg total) |
| Purity (each component) | ≥99.0% by RP-HPLC |
| Endotoxin | <1.0 EU/mg |
| Long-Term Storage (lyophilised, sealed) | −20°C, protected from light and moisture |
| Transit | Ambient; cold-chain packaging included |
Note: Reconstituted solution storage, solvent selection, working concentration, and stability period guidance are not provided, consistent with Core Research’s Research Use Only supply policy. Researchers should refer to their institutional SOPs and the published literature for handling reconstituted peptide solutions. Stability period is stated on the batch-specific CoA.
Regulatory Status and Compliance
CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin are research compounds without approved medicinal product status in the United Kingdom, European Union, or United States. Neither compound is listed as a controlled substance under the UK Misuse of Drugs Act 1971 or the US Controlled Substances Act. Both peptides appear on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are therefore prohibited in competitive sport. All orders are subject to our Terms and Conditions and Research Use Policy. Purchasers are responsible for ensuring compliance with all applicable national and institutional regulations governing the acquisition and use of research peptides.
Research context
The published literature on this material is summarised in the laboratory guides linked below. This record describes the material as supplied: identity, format, analytics, storage and documentation. It does not describe effects, and none should be inferred from the catalogue category.
For Research Use Only
CJC-1295 No DAC and Ipamorelin are supplied exclusively for in vitro laboratory research. Not for human or veterinary use. No dosing, reconstitution, or administration guidance is provided.
